11 stories found
Spyre Therapeutics' stock dropped significantly after the company reported disappointing and mixed Phase 2 trial data for its rheumatoid arthritis asset, SPY072. The results have led to investor concerns regarding the drug's efficacy.
Spyre Therapeutics (SYRE) is being evaluated as one of the small-cap stocks currently experiencing significant momentum and investor interest.
Spyre Therapeutics (SYRE) announced stellar results from its ulcerative colitis (UC) treatment trial, causing its stock to reach a four-year high.
Analysts have provided insights on several healthcare companies, including Integer Holdings (ITGR), Spyre Therapeutics (SYRE), and Tandem Diabetes Care (TNDM).
Spyre Therapeutics (SYRE) is listed among the top 12 high short interest stocks identified for their highest upside potential. This suggests market analysts see significant growth prospects despite current short positions.
Spyre Therapeutics (SYRE) has been highlighted as a preferred stock among elite money managers, indicating strong investor interest in the company.
National Healthcare Properties has announced the commencement of its public offering.
Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.
Multiple companies have released their recent financial performance, detailing GAAP or Non-GAAP earnings per share and revenue figures. These reports indicate whether the companies met, beat, or missed analyst expectations for their latest reporting period.
Spyre Therapeutics has priced an upsized stock deal, raising $403 million in gross proceeds, which significantly exceeds its initial target of $300 million.
Spyre Therapeutics stock has seen a significant surge over the past year, with a recent $10.5 million buy increasing a stake to $78 million.